Gabapentin
Product Images NDC 69677-208

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 69677-208). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mas Management Group, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin 300mg (Gabapentin 300mg)

Label for Gabapentin 300 mg capsules by Mas Management Group, Inc., NDC 69677-208-30. The label indicates a bottle containing 30 capsules, each with 300 mg of Gabapentin. Capsules are buff-colored, opaque, hard gelatin with 'IP 102' printed on both cap and body. Instructions for storage and packaging details are also provided.*

FDA Label Image

1 (Gabapentin Capsules Usp 1)

Formula representing the calculation of creatinine clearance (CLCr), showing variables for age in years, weight in kilograms, serum creatinine in mg/dL, and a multiplication factor for female patients.*

FDA Label Image

2 (Gabapentin Capsules Usp 2)

Chemical structure of gabapentin displaying a cyclohexane ring bonded to a carbon attached to an amino group (CH2NH2) and an acetic acid group (CH2CO2H). This structural diagram reflects the molecular framework of the active ingredient gabapentin.*

FDA Label Image

3 (Gabapentin Capsules Usp 3)

A line graph comparing mean pain scores over an 8-week period for placebo and Gabapentin 3600 mg/day. The x-axis shows weeks from baseline to 8, and the y-axis represents mean pain scores from 0 to 10. The graph indicates a 4-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

4 (Gabapentin Capsules Usp 4)

A line graph depicting mean pain scores over a 7-week period comparing placebo with Gabapentin at doses of 1800 mg/day and 2400 mg/day. The x-axis represents weeks with a 3-week dose titration period followed by a 4-week fixed dose period, and the y-axis shows mean pain scores from 0 to 10. Gabapentin groups show a decrease in pain scores over time compared to placebo.*

FDA Label Image

5 (Gabapentin Capsules Usp 5)

Bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing the percentage of responders between placebo (PBO) and gabapentin (GBP) groups at different dosages in two studies. Study 1 shows 12% responders for placebo and 29% for GBP 3600 mg. Study 2 shows 14% responders for placebo, 32% for GBP 1800 mg, and 34% for GBP 2400 mg, with statistical significance indicated for GBP groups.*

FDA Label Image

6 (Gabapentin Capsules Usp 6)

A scatter plot chart showing the difference (%) on the y-axis versus daily dose (mg) on the x-axis. The chart compares data from three studies labeled a, b, and c, with study a represented by black squares, study b by gray squares, and study c by white squares. The data points show variation in difference percentages across daily doses ranging from approximately 600 mg to 1800 mg.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.